Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Role of TNF in sickness behavior and allodynia during the acute phase of Chagas' disease.

Rodríguez-Angulo H, Thomas LE, Castillo E, Cárdenas E, Mogollón F, Mijares A.

Exp Parasitol. 2013 Aug;134(4):422-9. doi: 10.1016/j.exppara.2013.05.006. Epub 2013 May 14.

PMID:
23684908
2.

Etanercept induces low QRS voltage and autonomic dysfunction in mice with experimental Chagas disease.

Rodríguez-Angulo H, García O, Castillo E, Cardenas E, Marques J, Mijares A.

Arq Bras Cardiol. 2013 Sep;101(3):205-10. doi: 10.5935/abc.20130149. Epub 2013 Jul 23. English, Portuguese.

3.

Trypanosoma cruzi-induced depressive-like behavior is independent of meningoencephalitis but responsive to parasiticide and TNF-targeted therapeutic interventions.

Vilar-Pereira G, Silva AA, Pereira IR, Silva RR, Moreira OC, de Almeida LR, de Souza AS, Rocha MS, Lannes-Vieira J.

Brain Behav Immun. 2012 Oct;26(7):1136-49. doi: 10.1016/j.bbi.2012.07.009. Epub 2012 Jul 25.

4.
5.

Importance of TNF-alpha in the course of acute infection with Trypanosoma cruzi: influence of its inhibition by pentoxifylline treatment.

Andrade SG, Magalhães Ldos A, Pessina DH.

Mem Inst Oswaldo Cruz. 2008 Feb;103(1):21-6. Epub 2008 Jan 31.

6.

Evidence for a protective role of tumor necrosis factor in the acute phase of Trypanosoma cruzi infection in mice.

Lima EC, Garcia I, Vicentelli MH, Vassalli P, Minoprio P.

Infect Immun. 1997 Feb;65(2):457-65.

7.
8.

Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.

Bhatia V, Garg NJ.

Clin Vaccine Immunol. 2008 Aug;15(8):1158-64. doi: 10.1128/CVI.00144-08. Epub 2008 Jun 11.

9.

Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice.

Basso B, Cervetta L, Moretti E, Carlier Y, Truyens C.

Vaccine. 2004 May 7;22(15-16):1868-72.

PMID:
15121297
10.

Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88.

Campos MA, Closel M, Valente EP, Cardoso JE, Akira S, Alvarez-Leite JI, Ropert C, Gazzinelli RT.

J Immunol. 2004 Feb 1;172(3):1711-8.

11.

Chronic Chagas' disease in rhesus monkeys (Macaca mulatta): evaluation of parasitemia, serology, electrocardiography, echocardiography, and radiology.

Carvalho CM, Andrade MC, Xavier SS, Mangia RH, Britto CC, Jansen AM, Fernandes O, Lannes-Vieira J, Bonecini-Almeida MG.

Am J Trop Med Hyg. 2003 Jun;68(6):683-91.

PMID:
12887027
12.

Involvement of nitric oxide (NO) and TNF-alpha in the oxidative stress associated with anemia in experimental Trypanosoma cruzi infection.

Malvezi AD, Cecchini R, de Souza F, Tadokoro CE, Rizzo LV, Pinge-Filho P.

FEMS Immunol Med Microbiol. 2004 May 1;41(1):69-77.

13.

Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas' heart disease.

Pereira IR, Vilar-Pereira G, Silva AA, Moreira OC, Britto C, Sarmento ED, Lannes-Vieira J.

Mediators Inflamm. 2014;2014:798078. doi: 10.1155/2014/798078. Epub 2014 Jul 22.

14.

3-Hydroxy kynurenine treatment controls T. cruzi replication and the inflammatory pathology preventing the clinical symptoms of chronic Chagas disease.

Knubel CP, Martínez FF, Acosta Rodríguez EV, Altamirano A, Rivarola HW, Diaz Luján C, Fretes RE, Cervi L, Motrán CC.

PLoS One. 2011;6(10):e26550. doi: 10.1371/journal.pone.0026550. Epub 2011 Oct 19.

15.

Trypanosoma cruzi reinfections provoke synergistic effect and cardiac beta-adrenergic receptors' dysfunction in the acute phase of experimental Chagas' disease.

Bustamante JM, Rivarola HW, Fernández AR, Enders JE, Ricardo F, d'Oro Gloria DL, Palma JA, Paglini-Oliva PA.

Exp Parasitol. 2003 Mar-Apr;103(3-4):136-42.

PMID:
12880590
16.

TNF-α is involved in the abnormal thymocyte migration during experimental Trypanosoma cruzi infection and favors the export of immature cells.

Pérez AR, Berbert LR, Lepletier A, Revelli S, Bottasso O, Silva-Barbosa SD, Savino W.

PLoS One. 2012;7(3):e34360. doi: 10.1371/journal.pone.0034360. Epub 2012 Mar 26.

17.

Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model.

Zanella JM, Burright EN, Hildebrand K, Hobot C, Cox M, Christoferson L, McKay WF.

Spine (Phila Pa 1976). 2008 Feb 1;33(3):227-34. doi: 10.1097/BRS.0b013e318162340a.

PMID:
18303453
18.

Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice.

Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O.

Acta Diabetol. 2011 Jun;48(2):135-42. doi: 10.1007/s00592-010-0237-x. Epub 2010 Nov 23.

PMID:
21104419
20.

Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion.

Malleo G, Mazzon E, Genovese T, Di Paola R, Muià C, Centorrino T, Siriwardena AK, Cuzzocrea S.

Shock. 2007 May;27(5):542-51.

PMID:
17438460

Supplemental Content

Support Center